Why do people develop antibodies to food? While clinicians have long observed that healthy humans develop a particular type ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data was presented at the 62nd European Renal Association Congress (ERA Congress), which took place in Vienna, ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...